The most commonly reported side effects across this peptide class (nausea, constipation, vomiting, diarrhea, and abdominal discomfort) are consistent with how the peptide acts on the gut. Their presence at low or moderate intensity is consistent with the mechanism.

Their absence isn't evidence of higher product quality. Their presence in the expected GI pattern isn't evidence of lower product quality. The studies reported these side effects at the rates they reported them across multiple separately-manufactured batches of the same molecule.

Side effects are signals to interpret, not verdicts on the product. The threshold worth knowing has three parts: a baseline understanding of what the expected GI pattern looks like during dose-up, plus a clear sense of when something is no longer the routine pattern, plus clinician access to translate symptoms into action.